Close Menu

EGFR Biomarkers

News and reporting on EGFR biomarkers.

The Phase I trial will assess BBP-398's safety and anti-tumor activity in cancers with MAPK signaling pathway genetic mutations, including mutations in RAS genes.

The EGFR deep learning score, the researchers believe, could provide a faster and less invasive method compared to tissue-based biomarker tests.


The Phase I/II trials will study Reqorsa in combination with Merck's Keytruda and AstraZeneca's Tagrisso in certain molecularly defined lung cancer subgroups.

Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.

The drug firm expects to begin a Phase I/II tumor-agnostic trial of the drug in genetically defined cancers in the second half of 2021.

The company submitted data from the ADAURA study, and the agency is slated to issue a decision on the application by the first quarter in 2021.

A pooled analysis of clinical trials and real-world data shows that the anti-tumor activity of Boehringer Ingelheim's TKI is unaffected by patients' ethnicity.

AstraZeneca's EGFR-inhibitor has now demonstrated an 'overwhelming' disease-free survival and CNS recurrence benefit, but overall survival benefit remains unknown.

The MET inhibitor OMO-1 will be studied with Allist's EGFR inhibitor furmonertinib in patients with MET-positive, EGFR-mutated cancers.

NICE is reversing its earlier negative recommendation for the lung cancer drug after AstraZeneca agreed to provide it at a discount.